Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma

Patients with active chronic lymphocytic leukemia or multiple myeloma mounted lower antibody responses to mRNA COVID-19 vaccination than healthy individuals, according to data from two reports published in Blood.

LOXO-305, a novel non-covalent BTK inhibitor, was active in B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, according to data presented at the ASH Annual Meeting and Exposition.

Five-year data from the MURANO study showed a continued PFS benefit with venetoclax-rituximab vs. bendamustine-rituximab among patients with relapsed or refractory chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia with undetectable minimal residual disease after first-line venetoclax plus ibrutinib achieved similar 1-year DFS whether they then received ibrutinib or placebo, according to study results.